Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
Rad2Nivo trial (nivolumab): what clinicians have said so far
Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
- NCT04109729 ↗
- Active, not recruiting
- University of Utah
- Focused size, estimated: 1–150 verified statements once built
Discussed at: 2026 ASCO Annual Meeting
We haven't built an HCP commentary report on Rad2Nivo (nivolumab plus radium-223 in metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Rad2Nivo so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase IB Study of Nivolumab in Combination With Radium-223 in Men With Metastatic Castration Resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Nivolumab; Radium-223
- Arms
- All patients · Experimental
- Enrollment
- 39 (estimated)
- Primary outcomes
- To assess the frequency of grade 3 or greater non-hematologic treatment-emergent adverse events when combining nivolumab with Radium-223
- To assess the ctDNA reduction after 6 weeks of nivolumab treatment.
- Sponsor
- University of Utah
- Start
- Sep 16, 2020
- Primary completion
- Apr 28, 2026
- Results posted
- No
- Registry record
- NCT04109729 · updated Jun 1, 2026